MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Tan, Katharine L. Lewis, Timothy S. Fenske, Catherine C. Coombs, Ian W. Flinn, D. J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech‐Marańda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj C. Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael Wang